


NanoTherix Revenue
Biotechnology Research • Leuven, Flemish Region, Belgium • 1-10 Employees
NanoTherix revenue & valuation
| Annual revenue | $427,775 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,400,000 |
| Total funding | No funding |
Key Contact at NanoTherix
David Bramhill
Chief Technology Officer
Company overview
| Headquarters | Ambachtenlaan 1, Heverlee, Flemish Region 3001, BE |
| Website | |
| NAICS | 541714 |
| Founded | 2025 |
| Employees | 1-10 |
About NanoTherix
NanoTherix is pioneering NDCentrix®, a fully proprietary Nanobody–Drug Conjugate (NDC) platform that converts single-domain antibodies into next wave precision therapeutics. Our conjugates deliver higher, faster, deeper intratumoral exposure while minimizing healthy-tissue uptake. We are building NDCentrix® as the engine for our own oncology pipeline - where ADCs underperform - and for out-licensing to partners.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
NanoTherix has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
NanoTherix has never raised funding before.
Frequently asked questions
4.8
40,000 users



